Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma

Bristol Myers Squibb's iberdomide, a first-in-class CELMoD protein degrader drug, received accelerated FDA approval for treating adults with multiple myeloma who have had prior therapy. The approval sets a new regulatory precedent for therapies targeting this blood cancer, with iberdomide used alongside Johnson & Johnson’s Darzalex Faspro and dexamethasone.

This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.